RT Journal Article
SR Electronic
T1 Optimizing the spatio-temporal allocation of COVID-19 vaccines: Italy as a case study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.06.21256732
DO 10.1101/2021.05.06.21256732
A1 Joseph C. Lemaitre
A1 Damiano Pasetto
A1 Mario Zanon
A1 Enrico Bertuzzo
A1 Lorenzo Mari
A1 Stefano Miccoli
A1 Renato Casagrandi
A1 Marino Gatto
A1 Andrea Rinaldo
YR 2021
UL http://medrxiv.org/content/early/2021/05/13/2021.05.06.21256732.abstract
AB While SARS-CoV-2 vaccine distribution campaigns are underway across the world, communities face the challenge of a fair and effective distribution of limited supplies. We wonder whether suitable spatial allocation strategies might significantly improve a campaign’s efficacy in averting damaging outcomes. To that end, we address the problem of optimal control of COVID-19 vaccinations in a country-wide geographic and epidemiological context characterized by strong spatial heterogeneities in transmission rate and disease history. We seek the vaccine allocation strategies in space and time that minimize the number of infections in a prescribed time horizon. We examine scenarios of unfolding disease transmission across the 107 provinces of Italy, from January to April 2021, generated by a spatially explicit compartmental COVID-19 model tailored to the Italian geographic and epidemiological context. We develop a novel optimal control framework to derive optimal vaccination strategies given the epidemiological projections and constraints on vaccine supply and distribution logistic. Optimal schemes significantly outperform simple alternative allocation strategies based on incidence, population distribution, or prevalence of susceptibles in each province. Our results suggest that the complex interplay between the mobility network and the spatial heterogeneities imply highly non-trivial prioritization of local vaccination campaigns. The extent of the overall improvements in the objectives grants further inquiry aimed at refining other possibly relevant factors so far neglected. Our work thus provides a proof-of-concept of the potential of optimal control for complex and heterogeneous epidemiological contexts at country, and possibly global, scales.Author summary The development of vaccines has sparked high hopes towards the control of SARS-CoV-2 transmission without resorting to extensive community-wide restrictions. A fundamental unanswered question concerns the best possible allocation of a limited vaccine stock in space and time given a specific goal. We address this through an optimal control framework based on a reliable spatially explicit COVID-19 epidemiological model, where vaccine distribution is optimized under supply and deployment capacity constraints. This tool provides strategies for optimal allocations in different scenarios, yielding important improvements over considered alternatives. By accounting for spatial heterogeneities and human mobility networks, the presented approach complements currently used allocation methods based on criteria such as age or risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJCL and AR acknowledge funding from the Swiss National Science Foundation via the project "Optimal control of intervention strategies for waterborne disease epidemics" (200021--172578). AR, EB and DP acknowledge funding from Fondazione Cassa di Risparmio di Padova e Rovigo (IT) through its grant 55722.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None neededAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full framework and analysis code to generate the figures is available here: https://github.com/jcblemai/COVID-19_italy-vaccination-oc https://github.com/jcblemai/COVID-19_italy-vaccination-oc